Novel subtypes of NPM1-mutated AML with distinct outcome

Acute myeloid leukemia (AML) is heterogeneous with one common subtype recognized by the presence of recurrent mutation of nucleophosmin-1 (NPM1). Emerging evidence indicates that within NPM1 mutated AML there is variation in outcome which challenges how best to characterize and treat the individual...

Full description

Bibliographic Details
Main Authors: Arvind Singh Mer, Mark D. Minden, Benjamin Haibe-Kains, Aaron D. Schimmer
Format: Article
Language:English
Published: Taylor & Francis Group 2021-07-01
Series:Molecular & Cellular Oncology
Subjects:
Online Access:http://dx.doi.org/10.1080/23723556.2021.1924600
_version_ 1827809361976623104
author Arvind Singh Mer
Mark D. Minden
Benjamin Haibe-Kains
Aaron D. Schimmer
author_facet Arvind Singh Mer
Mark D. Minden
Benjamin Haibe-Kains
Aaron D. Schimmer
author_sort Arvind Singh Mer
collection DOAJ
description Acute myeloid leukemia (AML) is heterogeneous with one common subtype recognized by the presence of recurrent mutation of nucleophosmin-1 (NPM1). Emerging evidence indicates that within NPM1 mutated AML there is variation in outcome which challenges how best to characterize and treat the individual patient. Our recent findings show that there are two distinct (primitive and committed) subtypes within NPM1 mutated AML patients. These subtypes exhibit specific molecular characteristics, disease differentiation states, patient survival, and differential drug responses.
first_indexed 2024-03-11T22:40:08Z
format Article
id doaj.art-b14aa391fd0d47b1a9701abe91233208
institution Directory Open Access Journal
issn 2372-3556
language English
last_indexed 2024-03-11T22:40:08Z
publishDate 2021-07-01
publisher Taylor & Francis Group
record_format Article
series Molecular & Cellular Oncology
spelling doaj.art-b14aa391fd0d47b1a9701abe912332082023-09-22T09:19:43ZengTaylor & Francis GroupMolecular & Cellular Oncology2372-35562021-07-018410.1080/23723556.2021.19246001924600Novel subtypes of NPM1-mutated AML with distinct outcomeArvind Singh Mer0Mark D. Minden1Benjamin Haibe-Kains2Aaron D. Schimmer3University Health NetworkUniversity Health NetworkUniversity Health NetworkUniversity Health NetworkAcute myeloid leukemia (AML) is heterogeneous with one common subtype recognized by the presence of recurrent mutation of nucleophosmin-1 (NPM1). Emerging evidence indicates that within NPM1 mutated AML there is variation in outcome which challenges how best to characterize and treat the individual patient. Our recent findings show that there are two distinct (primitive and committed) subtypes within NPM1 mutated AML patients. These subtypes exhibit specific molecular characteristics, disease differentiation states, patient survival, and differential drug responses.http://dx.doi.org/10.1080/23723556.2021.1924600acute myeloid leukemiabiomarkerssubtypemachine learningsystems biology
spellingShingle Arvind Singh Mer
Mark D. Minden
Benjamin Haibe-Kains
Aaron D. Schimmer
Novel subtypes of NPM1-mutated AML with distinct outcome
Molecular & Cellular Oncology
acute myeloid leukemia
biomarkers
subtype
machine learning
systems biology
title Novel subtypes of NPM1-mutated AML with distinct outcome
title_full Novel subtypes of NPM1-mutated AML with distinct outcome
title_fullStr Novel subtypes of NPM1-mutated AML with distinct outcome
title_full_unstemmed Novel subtypes of NPM1-mutated AML with distinct outcome
title_short Novel subtypes of NPM1-mutated AML with distinct outcome
title_sort novel subtypes of npm1 mutated aml with distinct outcome
topic acute myeloid leukemia
biomarkers
subtype
machine learning
systems biology
url http://dx.doi.org/10.1080/23723556.2021.1924600
work_keys_str_mv AT arvindsinghmer novelsubtypesofnpm1mutatedamlwithdistinctoutcome
AT markdminden novelsubtypesofnpm1mutatedamlwithdistinctoutcome
AT benjaminhaibekains novelsubtypesofnpm1mutatedamlwithdistinctoutcome
AT aarondschimmer novelsubtypesofnpm1mutatedamlwithdistinctoutcome